Antibody-drug conjugates (ADCs) are an effect therapeutic modality to deliver potent cytotoxic molecules to tumor cells bearing a specific antigen.
A paper now published in Haematologica presents the novel anti-CD19 ADC huB4-DGN462, developed by Colleagues from Immunogen and characterized for its anti-lymphoma activity in Bertoni’s lab.
As shown by the work of Chiara Tarantelli and her Colleagues, huB4-DGN462 has an improved activity when compared with coltuximab ravtansine (SAR3419), an anti-CD19 ADC already in the clinics, and is an attractive candidate for clinical investigation in patients with B-cell malignancies.
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W. Hicks *, Chiara Tarantelli *, Alan Wilhem, Eugenio Gaudio, Min Li, Alberto J. Arribas, Filippo Spriano, Roberta Bordone, Luciano Cascione, Katharine C. Lai, Qifeng Qiu, Monica Taborelli, Davide Rossi, Georg Stussi, Emanuele Zucca, Anastasios Stathis, Callum M. Sloss ^, Francesco Bertoni ^
*, co-first authors; ^, co-corresponding authors.
Haematologica. 2019 Feb 7. pii: haematol.2018.211011. doi: 10.3324/haematol.2018.211011. [Epub ahead of print]